300 milligram tablets of Budeprion XL have lost their approval from the Food and Drug Administration following testing which suggested the key ingredient in this drug was not being adequately distributed in the bloodstream. This generic counterpart to the Wellbutrin XL antidepressant allegedly distributes the active ingredient quicker than Wellbutrin proper, and many people have reported that their depression has not ebbed in conjunction with the drug and that they have had to put up with headaches. The 150 milligram version of the generic from Teva Pharmaceuticals and Impax Labs is still available and is not thought to pose a threat.
Click here for more information.